View Older Stories View More Recent Stories
-
HSBC Downgrades Biogen (BIIB) to Reduce
-
Stoke Therapeutics and Biogen present zorevunersen data at epilepsy meeting
-
Eisai and Biogen present data showing LEQEMBI binding to toxic proteins
-
Stoke and Biogen to present zorevunersen data at epilepsy conference
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
-
Biogen partners with Dayra to develop oral macrocyclic peptides
-
Stoke and Biogen publish data showing Dravet syndrome severity
-
Biogen (BIIB): High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
-
Where can biotech stocks go from here? RBC answers
-
Stifel lifts Biogen to Buy, sees potential Alzheimer's narrative shift
-
Stifel Upgrades Biogen (BIIB) to Buy, 'Risk/Reward Shifting Favorably With Clinical Catalysts'
-
Biogen to present felzartamab data at kidney disease conference
-
Biogen (BIIB) PT Raised to $157 at Bernstein SocGen Group
-
Biogen (BIIB) PT Lowered to $250 at Baird
-
Biogen (BIIB) PT Raised to $185 at Guggenheim
-
Biogen (BIIB) Tops Q3 EPS by 93c; updates guidance
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
Biogen licenses oral drug from Vanqua Bio for $70 million upfront
-
Truist Securities: 'Is Biotech Back?!'
-
Biogen expects $2 million charge in third quarter 2025
-
Biotech stocks: Q3 earnings preview
-
Biogen and Stoke present 3-year zorevunersen data for Dravet syndrome
-
Biogen (BIIB) PT Lowered to $217 at RBC Capital
-
Eisai and Biogen launch at-home injection option for alzheimer's drug
-
Jefferies sees 'an attractive setup' in this large biotech stock
-
Jefferies Starts Biogen (BIIB) at Buy
-
Eisai and Biogen receive approval for LEQEMBI in Australia
-
FDA requests technical updates for Biogen's high dose nusinersen application
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Biogen gets European approval for postpartum depression treatment
-
Canaccord Genuity Reiterates Buy Rating on Biogen (BIIB)
-
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
-
FDA approves Eisai's LEQEMBI IQLIK for Alzheimer's maintenance treatment
-
Biogen and Stoke present three-year zorevunersen data for Dravet syndrome
-
Stoke Therapeutics and Biogen present 3-year zorevunersen data for Dravet
-
Stoke Therapeutics and Biogen to present zorevunersen data at epilepsy congress
-
Biogen (BIIB) PT Raised to $118 at Piper Sandler
-
U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
-
Biogen (BIIB) PT Raised to $194 at H.C. Wainwright
-
Biogen (BIIB) PT Lowered to $144 at Morgan Stanley
-
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) Tops Q2 EPS by $1.48, Beats on Revenue; Offers Guidance
-
Eisai and Biogen present two-year LEQEMBI real-world study results
-
Eisai and Biogen present data on subcutaneous LEQEMBI maintenance dosing
-
ZURZUVAE receives positive CHMP opinion for postpartum depression treatment
-
Truist Securities Starts Biogen (BIIB) at Hold
-
Biogen plans $2 billion manufacturing investment in North Carolina
-
U.S. large biotech stocks Q2 earnings preview
